IL283771A - Analosomes for the delivery of intracellular therapeutic modalities - Google Patents
Analosomes for the delivery of intracellular therapeutic modalitiesInfo
- Publication number
- IL283771A IL283771A IL283771A IL28377121A IL283771A IL 283771 A IL283771 A IL 283771A IL 283771 A IL283771 A IL 283771A IL 28377121 A IL28377121 A IL 28377121A IL 283771 A IL283771 A IL 283771A
- Authority
- IL
- Israel
- Prior art keywords
- anellosomes
- therapeutic modalities
- intracellular therapeutic
- delivering intracellular
- delivering
- Prior art date
Links
- 230000003834 intracellular effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778851P | 2018-12-12 | 2018-12-12 | |
| US201862778866P | 2018-12-12 | 2018-12-12 | |
| PCT/US2019/065874 WO2020123753A2 (en) | 2018-12-12 | 2019-12-12 | Anellosomes for delivering intracellular therapeutic modalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283771A true IL283771A (en) | 2021-07-29 |
Family
ID=69160334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283771A IL283771A (en) | 2018-12-12 | 2021-06-07 | Analosomes for the delivery of intracellular therapeutic modalities |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220040117A1 (enExample) |
| EP (1) | EP3894567A2 (enExample) |
| JP (2) | JP2022514501A (enExample) |
| KR (1) | KR20210131308A (enExample) |
| CN (1) | CN114127302A (enExample) |
| AU (1) | AU2019396516A1 (enExample) |
| BR (1) | BR112021009282A2 (enExample) |
| CA (1) | CA3119339A1 (enExample) |
| IL (1) | IL283771A (enExample) |
| MX (1) | MX2021006941A (enExample) |
| WO (1) | WO2020123753A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123795A2 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering protein replacement therapeutic modalities |
| MX2021006977A (es) * | 2018-12-12 | 2021-10-13 | Flagship Pioneering Innovations V Inc | Anellosomas y metodos de uso. |
| WO2021252955A1 (en) * | 2020-06-12 | 2021-12-16 | Flagship Pioneering Innovations V, Inc. | Tandem anellovirus constructs |
| US20250059559A1 (en) * | 2021-12-15 | 2025-02-20 | Flagship Pioneering Innovations V, Inc. | Surface-modified viral particles and modular viral particles |
| US20240415978A1 (en) * | 2023-06-14 | 2024-12-19 | Flagship Pioneering Innovations V, Inc. | Anellovectors for delivery of effectors to the central nervous system |
| WO2025080985A1 (en) | 2023-10-13 | 2025-04-17 | Flagship Pioneering Innovations V, Inc. | Tissue specific anellovector delivery |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| KR20200038236A (ko) * | 2017-06-13 | 2020-04-10 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 큐론을 포함하는 조성물 및 그의 용도 |
-
2019
- 2019-12-12 CA CA3119339A patent/CA3119339A1/en active Pending
- 2019-12-12 US US17/413,123 patent/US20220040117A1/en active Pending
- 2019-12-12 AU AU2019396516A patent/AU2019396516A1/en active Pending
- 2019-12-12 CN CN201980091151.3A patent/CN114127302A/zh active Pending
- 2019-12-12 KR KR1020217021774A patent/KR20210131308A/ko active Pending
- 2019-12-12 JP JP2021533523A patent/JP2022514501A/ja not_active Withdrawn
- 2019-12-12 BR BR112021009282-0A patent/BR112021009282A2/pt unknown
- 2019-12-12 MX MX2021006941A patent/MX2021006941A/es unknown
- 2019-12-12 WO PCT/US2019/065874 patent/WO2020123753A2/en not_active Ceased
- 2019-12-12 EP EP19836313.7A patent/EP3894567A2/en active Pending
-
2021
- 2021-06-07 IL IL283771A patent/IL283771A/en unknown
-
2024
- 2024-05-07 JP JP2024075358A patent/JP2024102242A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210131308A (ko) | 2021-11-02 |
| CA3119339A1 (en) | 2020-06-18 |
| CN114127302A (zh) | 2022-03-01 |
| JP2024102242A (ja) | 2024-07-30 |
| JP2022514501A (ja) | 2022-02-14 |
| MX2021006941A (es) | 2021-11-17 |
| EP3894567A2 (en) | 2021-10-20 |
| BR112021009282A2 (pt) | 2021-08-17 |
| WO2020123753A3 (en) | 2020-07-23 |
| US20220040117A1 (en) | 2022-02-10 |
| WO2020123753A2 (en) | 2020-06-18 |
| AU2019396516A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201820166D0 (en) | Therapeutic agents | |
| SG11202104461XA (en) | Therapeutic methods | |
| GB201820165D0 (en) | Therapeutic agents | |
| GB201709456D0 (en) | Therapeutic agents | |
| IL283778A (en) | Analosomes for delivery of secreted therapeutic modalities | |
| IL283771A (en) | Analosomes for the delivery of intracellular therapeutic modalities | |
| IL283781A (en) | Analosomes for the delivery of protein replacement therapeutics | |
| IL250990A0 (en) | Materials for human care | |
| GB201603104D0 (en) | Therapeutic agents | |
| SG11202103253YA (en) | Therapeutic compounds | |
| GB201805816D0 (en) | Therapeutic agents | |
| GB201608797D0 (en) | Therapeutic use | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| GB201808150D0 (en) | Therapeutic compounds | |
| ZA202001418B (en) | Therapeutic indazoles | |
| GB201700553D0 (en) | Therapeutic agents | |
| GB201700526D0 (en) | Therapeutic use | |
| GB201909493D0 (en) | Therapeutic interactions | |
| GB201409653D0 (en) | Pyrrolobenzodiazepine therapeutic agents | |
| HK40052985A (en) | Anellosomes for delivering intracellular therapeutic modalities | |
| GB201620948D0 (en) | Therapeutic agents | |
| GB201616563D0 (en) | Therapeutic agents | |
| GB201820164D0 (en) | Therapeutic agents | |
| GB201820162D0 (en) | Therapeutic agents | |
| GB201820172D0 (en) | Therapeutic agents |